Concepedia

Cardiovascular Disease After Aromatase Inhibitor Use

Reina Haque, Jiaxiao Shi, Joanne E. Schottinger, Joanie Chung, Chantal Avila, Britta Amundsen, Xiaoqing Xu, Ana Barac, Rowan T. Chlebowski

JAMA Oncology · 2016 · 101 citations · 25 references

DOIFull text

Open access

Abstract

The risk of the most serious cardiovascular events (cardiac ischemia or stroke) was not elevated in AI-only users compared with tamoxifen users. The finding that other CVD events combined were greater in AI users requires further study.

References

25

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

, , +7

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

Paul E. Goss, James N. Ingle, Silvana Martino et al. · JNCI Journal of the National Cancer Institute · 2005 · 1.1K citations · Full text

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Paul E. Goss, James N. Ingle, José E. Alés‐Martínez et al. · New England Journal of Medicine · 2011 · 952 citations · Full text

Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study

Jennifer L. Patnaik, Tim Byers, Carolyn DiGuiseppi et al. · Breast Cancer Research · 2011 · 874 citations · Full text

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Harold J. Burstein, Sarah Temin, Holly Anderson et al. · Journal of Clinical Oncology · 2014 · 790 citations · Full text